In recent years, there has been a major paradigm shift in the management of non-small cell
lung cancer (NSCLC). NSCLC should now be further sub-classified by histology and driver …

Docetaxel (Taxotere®) has been one of the most important chemotherapeutic drugs for
cancer treatment since 1996. Although a large number of clinical studies have been …

Purpose To provide evidence-based recommendations to update the American Society of
Clinical Oncology guideline on systemic therapy for stage IV non–small-cell lung cancer …

Purpose To conduct analyses exploring trial-level and patient-level associations between
overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) in …

Background: Multi-targeted vascular endothelial growth factor receptor (VEGFR) tyrosine
kinase inhibitors (TKIs) are known to cause cardiac toxicity, but the relative risk (RR) of QTc …

In many cancers, including non-small cell lung cancer (NSCLC), tumor angiogenesis
pathways have been identified as important therapeutic targets. Angiogenesis is essential in …

Background. Although genetic profiling of tumors is a potentially powerful tool to predict drug
sensitivity and resistance, its routine use has been limited because clinicians are often …

Purpose Vascular endothelial growth factor signaling pathway plays a crucial role in
angiogenesis and has become a promising target for cancer drug development. We aimed …

Background To determine the prevalence of RET rearrangement genes, RET copy number
gains and expression in tumor samples from four Phase III non-small-cell lung cancer …

Recognition of the vascular endothelial growth factor (VEGF) pathway as a key mediator of
angiogenesis has led to the clinical study of several VEGF and VEGF receptor (VEGFR) …